Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis (NASH). It is developing gemcabene, a novel, once-daily, oral therapy, for high risk cardiovascular patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy, and for those patients who present with NASH. The company was founded in 2008 and is headquartered in Livonia, Michigan.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GEMP
CUSIPN/A
Phone734-245-1700
Debt
Debt-to-Equity Ratio0.37
Current Ratio5.57
Quick Ratio5.57
Price-To-Earnings
Trailing P/E Ratio-2.39
Forward P/E Ratio-3.00
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.37 per share
Price / Book20.86
Profitability
EPS (Most Recent Fiscal Year)($3.23)
Net Income$-33,410,000.00
Net MarginsN/A
Return on Equity-233.06%
Return on Assets-118.56%
Miscellaneous
Employees18
Outstanding Shares14,230,000
Market Cap$112.01
Gemphire Therapeutics (NASDAQ:GEMP) Frequently Asked Questions
What is Gemphire Therapeutics' stock symbol?
Gemphire Therapeutics trades on the NASDAQ under the ticker symbol "GEMP."
How were Gemphire Therapeutics' earnings last quarter?
Gemphire Therapeutics Inc (NASDAQ:GEMP) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.63) by $0.05. View Gemphire Therapeutics' Earnings History.
When is Gemphire Therapeutics' next earnings date?
What price target have analysts set for GEMP?
6 brokerages have issued twelve-month target prices for Gemphire Therapeutics' stock. Their predictions range from $18.00 to $31.00. On average, they expect Gemphire Therapeutics' share price to reach $25.1667 in the next twelve months. This suggests a possible upside of 226.4% from the stock's current price. View Analyst Ratings for Gemphire Therapeutics.
What is the consensus analysts' recommendation for Gemphire Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gemphire Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Gemphire Therapeutics stock?
Here are some recent quotes from research analysts about Gemphire Therapeutics stock:
- 1. According to Zacks Investment Research, "Gemphire Therapeutics Inc. is a biopharmaceutical company. It focused on developing and commercializing therapies for the treatment of dyslipidemia. The company's product candidate is gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies. Gemphire Therapeutics Inc. is headquartered in Northville, Michigan. " (3/21/2018)
- 2. Canaccord Genuity analysts commented, "We believe gemcabene’s 40% hsCRP reduction is very meaningful, especially given that Novartis canikinumab reduced hsCRP and lowered Major Adverse Cardiac Events (MACE). In our view, gemcabene has lowering effects on important biomarkers beyond LDL, including triglycerides and hsCRP, differentiating the drug from competitors. Continue to anticipate positive INDIGO-1 data in 2018 We expect gemcabene to show a statistically significant reduction in triglycerides in the INDIGO-1 study in 2018, providing a major catalyst for shares to move higher. Importantly, many drugs can lower LDL cholesterol, but some have no effect on triglycerides, such as PCSK9 therapies." (10/13/2017)
Who are some of Gemphire Therapeutics' key competitors?
Some companies that are related to Gemphire Therapeutics include Sinovac Biotech (SVA), Dermira (DERM), Zymeworks (ZYME), Unum Therapeutics (UMRX), ZIOPHARM Oncology (ZIOP), ProMetic Life Sciences (PFSCF), Xeris Pharmaceuticals (XERS), American Brivision (Holding) (ABVC), Achillion Pharmaceuticals (ACHN), Albireo Pharma (ALBO), Savara (SVRA), Syros Pharmaceuticals (SYRS), Concert Pharmaceuticals (CNCE), GTX (GTXI) and Kindred Biosciences (KIN).
Who are Gemphire Therapeutics' key executives?
Gemphire Therapeutics' management team includes the folowing people:
- Dr. Charles L. Bisgaier Ph.D., Co-Founder, Chairman and Chief Scientific Officer (Age 64)
- Dr. Steven R. Gullans, Interim Chief Exec. Officer, Interim Pres & Director (Age 65)
- Mr. Jeffrey S. Mathiesen, Chief Financial Officer and Sec. (Age 57)
- Mr. Seth Reno MBA, Chief Commercial Officer (Age 51)
- Dr. Lee Golden M.D., Chief Medical Officer (Age 50)
When did Gemphire Therapeutics IPO?
(GEMP) raised $30 million in an initial public offering (IPO) on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.
Has Gemphire Therapeutics been receiving favorable news coverage?
News coverage about GEMP stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Gemphire Therapeutics earned a media sentiment score of 0.15 on Accern's scale. They also gave news stories about the company an impact score of 48.83 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
How do I buy shares of Gemphire Therapeutics?
Shares of GEMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gemphire Therapeutics' stock price today?
One share of GEMP stock can currently be purchased for approximately $7.71.
How big of a company is Gemphire Therapeutics?
Gemphire Therapeutics has a market capitalization of $112.01 million. The company earns $-33,410,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Gemphire Therapeutics employs 18 workers across the globe.
How can I contact Gemphire Therapeutics?
Gemphire Therapeutics' mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company can be reached via phone at 734-245-1700 or via email at [email protected]
MarketBeat Community Rating for Gemphire Therapeutics (NASDAQ GEMP)
MarketBeat's community ratings are surveys of what our community members think about Gemphire Therapeutics and other stocks. Vote "Outperform" if you believe GEMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GEMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
